Multi-Domain VNAR Constructs for Stable TNFα Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing VNARs are inefficient in forming dimeric, trimeric, and bispecific fusions, and current VNAR-based therapeutics for antigens like TNFα and ICOSL lack improved functional properties when linked in multivalent or multispecific formats.
Innovation Solution
Development of multi-domain specific binding molecules comprising two or more VNAR domains that recognize the same or different epitopes on a single antigen, with spacer sequences to enhance functionality, and inclusion of non-VNAR domains like TNF R1 and immunoglobulin Fc for improved therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VNARs are linked in multivalent or multispecific formats, then therapeutic efficacy and potency are improved, but formation efficiency and functional performance deteriorate
Solution Approach 1:
The patent segments the VNAR binding domains into separate modular units that can be independently optimized and then assembled through standardized fusion methods. This allows efficient formation of multivalent constructs while maintaining high therapeutic efficacy, as each VNAR domain retains its individual binding function while contributing to overall potency through multivalency.
Solution Approach 2:
The patent creates composite molecular constructs by fusing VNAR domains with heterologous polypeptides such as Fc regions, albumin binding domains, or cell penetrating peptides. These composite structures combine the high-affinity binding properties of VNARs with the advantageous properties of partner molecules, resulting in multivalent therapeutics with improved efficacy and extended half-life while maintaining efficient production.
2Duration of action of moving object
If VNARs are linked in multivalent or multisspecific formats, then potency and biological half-life are improved, but structural stability and folding efficiency worsen
Solution Approach 1:
The patent introduces spacer sequences as intermediary elements between VNAR domains and heterologous polypeptides. These spacers provide flexible linkers that maintain proper spatial orientation and distance between binding domains, preventing steric hindrance and ensuring correct folding. The spacers act as buffers that protect the VNAR domains from destabilizing interactions while allowing the formation of stable multivalent structures with extended half-life.
3Power
If VNARs are linked in multivalent or multispecific formats, then agonistic or antagonistic effects are enhanced, but molecular complexity and production difficulty increase
Solution Approach 1:
The patent merges multiple VNAR domains with different specificities into single polypeptide chains through gene fusion techniques. This combining approach creates multispecific therapeutics that can simultaneously engage multiple targets or epitopes, enhancing overall biological activity and potency. The merged constructs are produced as single homogeneous molecules, simplifying production compared to mixture approaches while achieving complex functional outcomes.
Data Source
AI summary
The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNFα) are also provided.